Using AI, researchers at MIT have developed new antibiotics for gonorrhoea and MRSA, two infections that are typically hard to treat. The team “trained the AI to help it learn how bacteria was affected by different molecular structures built of atoms in order to design new antibiotics,” writes Ruth Stainer for the Daily Mail. “[A]nything too similar to the current antibiotics available, or with the potential to be toxic to human beings, was eradicated.”
Researchers at MIT used AI to “design antibiotics that can tackle hard-to-treat infections gonorrhoea and MRSA,” reports ITV News. "Our work shows the power of AI from a drug design standpoint, and enables us to exploit much larger chemical spaces that were previously inaccessible,” says Prof. James Collins.
Using generative AI, researchers at MT have designed new antibiotics to combat MRSA and gonorrhea, reports James Gallagher for the BBC. "We're excited because we show that generative AI can be used to design completely new antibiotics," says Prof. James Collins. "AI can enable us to come up with molecules, cheaply and quickly and in this way, expand our arsenal, and really give us a leg up in the battle of our wits against the genes of superbugs."
Strand Therapeutics, co-founded Jake Becraft PhD '19, has developed a programmable drug that could one day shrink tumors in cancer patients, reports Amy Feldman for Forbes. “It shocked even us,” says Becraft. “You hope something happens, but you don’t expect to see a huge response because these patients have already proven to have cancers so resistant to treatment.”
Researchers at MIT are working to advance our understanding of acute Lyme disease and long Covid, reports Brianna Abbott for The Wall Street Journal. “What we’re trying to do is measure everything,” said Principal Scientist Michal Caspi Tal. “I want to find a way to give people hope.”
Researchers at MIT have designed an implantable device that can be used to administer a dose of glucagon to protect Type 1 diabetics from hypoglycemia, reports Amir Khollam. “The device, about the size of a quarter, sits under the skin and releases a dose of glucagon when blood sugar levels dip too low,” explains Khollam. “It can be activated manually or triggered wirelessly by a sensor.”
Researchers from MIT and other institutions have uncovered new pathways, along with identifying genes, that may contribute to the development of a new class of drugs to treat Alzheimer’s disease, reports John R. Ellement for The Boston Globe. “The drugs currently approved to treat Alzheimer’s have not been as successful as hoped,” Ellement explains. “Those drugs tend to target amyloid plaques in the brain, but the new research suggests other areas to target.”
Researchers from MIT and Harvard Medical School produced two new papers about the impact of a specific cytokine, or immune molecule, known as IL-17, on the brain when you’re sick. “Cytokines are well-known players in the immune response, helping to control inflammation and coordinate the responses of other immune cells,” reports Genetic Engineering & Biotechnology News. “A growing body of evidence suggests that some cytokines also influence the brain, leading to behavioral changes during illness.”
A team of researchers from MIT and Harvard Medical School are “deciphering the action of small immune system proteins in the brain and showing how, by exciting or inhibiting populations of neurons, they modulate anxiety and social behaviors,” writes Soline Roy of Le Figaro.
Newsha Ghaeli PhD '17, co-founder of BioBot Analytics, speaks with GBH Morning Edition host Mark Herz about the company’s role in helping public health officials during the Covid-19 pandemic. “When we started the company, the vision was really that wastewater is a source of very important source on human health,” says Ghaeli.
Researchers from MIT have “identified genes that the tuberculous bacteria rely on to survive and spread,” reports Allison DeAngelis for STAT. “Until now, very little was known about how tuberculous bacteria survived temperature changes, oxygen levels, humidity, and other environmental factors during the journey from one person’s lungs to another’s,” explains DeAngelis.
Prof. Ed Boyden and Prof. Li-Huei Tsai have “found that if gamma waves through non-invasive stimulation, were put back into baseline frequency, it could slow down the process in certain brain diseases such as Alzheimer’s,” reports Hansa Bhargava for Forbes.
Prof. Katharina Ribbeck speaks with New York Times reporter Nina Agrawal about her research studying the health and medical benefits of mucus. “Ribbeck’s research has shown that the sugars on mucins can effectively switch off mechanisms that the bacteria involved in strep throat or cholera, for example, or fungus in a yeast infection, use to go from innocuous to harmful,” explains Agrawal.
New Yorker reporter Dhruv Khullar spotlights how researchers from across MIT are using AI to advance drug development. Khullar highlights the MIT Jameel Clinic, the Broad Institute and various faculty members for their efforts in bridging the gap between AI and drug research. “With AI, we’re getting that much more efficient at finding molecules—and in some cases creating them,” says Prof. James Collins. “The cost of the search is going down. Now we really don’t have an excuse.”
Sonia Vallabh and Eric Minikel, senior group leaders from the Broad Institute have created a gene-editing tool to combat prion diseases, reports Karen Weintraub for USA Today. The approach “should also work against diseases such as Huntington's, Parkinson's, ALS and even Alzheimer's, which result from the accumulation of toxic proteins,” Weintraub writes.